Who’s Who: Ali Alhasan, CEO and founder of NanoPalm

NanoPalm founder and CEO Ali Alhasan. (Supplied)
Short Url
Updated 03 May 2024
Follow

Who’s Who: Ali Alhasan, CEO and founder of NanoPalm

  • Alhasan co-developed deep tech to leverage large language models for biotech discovery
  • He was granted the Outstanding Researcher Award from the International Institute for Nanotechnology in 2012

Ali Alhasan is CEO and founder of the company NanoPalm. He holds a Ph.D. in nanomedicine, with expertise in nano-drug delivery and gene therapy and five years of experience in executive management.

In his role as CEO, Alhasan formulates the strategic and business plans for accelerating therapy translation globally and trains talents in deep tech, nanotech, and gene editing tech.

Alhasan co-developed deep tech to leverage large language models for biotech discovery. He also co-invented Nanopalm’s biorobots for the delivery of gene editing primers and helped discover four nanomedicines for four different genetic diseases.

He is also an associate professor at King Abdulaziz City for Science and Technology and an adjunct professor at Alfaisal University, establishing collaboration agreements between the two.

As associate professor, he is the principal researcher for development and innovation in nanomedicine and the fourth industrial revolution.

In his role as adjunct professor, Alhasan teaches nanomedicine and mentors postgraduate and undergraduate students. He also co-established the Cancer Nanoscience Program.

Previously, Alhasan served in executive leadership roles at KACST as deputy at the Joint Centers of Excellence Program (2021), deputy of the Life Science and Environment Research Institute (2020), director of the Center of Excellence for Biomedicine (2020), and director of Strategic Initiatives (2016). 

Alhasan was a post-doctoral scholar at the University of California in 2015 and received his Ph.D. in the Interdepartmental Biological Sciences Program from Northwestern University in 2013. 

In 2008, he received a master’s degree in biotechnology also from Northwestern University, while in 2001, he received his bachelor’s degree in medical technology from King Abdulaziz University. 

Alhasan was granted the Leader of the Year award from the Ministry of Communication and Information Technology in 2024. In 2018, he received the Outstanding Investigator Award from KACST.

He was granted the Outstanding Researcher Award from the International Institute for Nanotechnology in 2012. 


Saudi Food and Drug Authority pioneering digital health safety

Updated 15 December 2025
Follow

Saudi Food and Drug Authority pioneering digital health safety

  • Digital foundation enabled the development of centralized dashboards that provide real-time analysis of adverse events
  • Major improvement has been the use of Robotic Process Automation (RPA) to ensure medication safety works smoothly

TOKYO: Saudi Arabia is establishing itself as a regional leader in digital health regulation by integrating advanced technologies into the Saudi Food and Drug Authority’s (SFDA) pharmacovigilance and cosmetic safety oversight.

In line with Vision 2030’s digital goals, these projects are creating new standards for using data to protect public health, according to the SFDA.

A report by the Oxford Business Group says the transformation began with modernising the National Pharmacovigilance Centre’s adverse reaction reporting system. Moving from paper-based submissions to the fully digital “Saudi Vigilance” platform marked a significant step forward.

The introduction of smart reporting forms with structured data fields and behavioural nudges grounded in psychological principles significantly improved reporting quality and completion rates.

This digital foundation enabled the development of centralised dashboards that provide real-time analysis of adverse events, enabling early identification of safety signals and under-reporting trends.

A major improvement has been the use of Robotic Process Automation (RPA) to ensure medication safety works smoothly. By letting computers handle repetitive tasks like sorting reports and checking data, the SFDA has become more efficient.

The new RPA system for identifying safety signals has also sped things up. These technology solutions have made work easier and happier employees by eliminating boring manual tasks.

The SFDA’s digital changes also help prevent risks by using new online learning tools. The aRMMs e-learning system, with training videos about high-risk medicines, has changed how health care workers learn. Adding digital safety steps directly into hospital computer systems has also made a big difference. This new approach puts safety alerts and learning materials directly into doctors’ daily work, ensuring important information reaches them when they need it.

Digital innovation has also helped prevent medication errors. Moving from the old Phonetic and Orthographic Computer Analysis system to the new Saudi Name Registration (SNR) platform has made it easier to spot potentially confusing drug names. With better computer programs that check both Arabic and English names, plus real-time alerts and automatic updates, the SNR system is a big step forward in ensuring the safety of medicines before they reach the market.

Looking ahead, the SFDA plans to use these digital changes to make cosmetic products safer as well.

Planned projects using artificial intelligence include computer systems that spot rule-breaking, automated ingredient checks, and tools that read customer feedback to identify early warning signs.

This digital strategy puts Saudi Arabia ahead in new ways of making rules. By using artificial intelligence, automation, and data analysis in its work, the SFDA is improving how it tracks medicine safety and preparing for further progress in keeping products safe for consumers.

All these efforts support Vision 2030’s goal of building a knowledge-based economy and keeping Saudi citizens as safe as possible.